Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,061 to 1,080 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comparative All-Cause Mortality Among a Large Population of Patients with Spinal Muscular Atrophy Versus Matched Controls. | Neurol Ther | 2022 | 34936050 | PubTator, text mining | PubMed |
| Systematic Literature Review to Identify Utility Values in Patients with Spinal Muscular Atrophy (SMA) and Their Caregivers. | Pharmacoeconomics | 2022 | 34907515 | PubTator, text mining | PubMed |
| Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries. | Pharmacoeconomics | 2022 | 34897574 | PubTator, text mining | PubMed |
| Splicing efficiency of minor introns in a mouse model of SMA predominantly depends on their branchpoint sequence and can involve the contribution of major spliceosome components. | RNA | 2022 | 34893560 | PubTator, text mining | PubMed |
| Antisense oligonucleotides targeting the SMN2 promoter region enhance SMN2 expression in spinal muscular atrophy cell lines and mouse model. | Hum Mol Genet | 2022 | 34888619 | PubTator, text mining | PubMed |
| Identification of specific gene methylation patterns during motor neuron differentiation from spinal muscular atrophy patient-derived iPSC. | Gene | 2022 | 34871761 | PubTator, text mining | PubMed |
| Biological function and molecular mechanism of SRSF3 in cancer and beyond. | Oncol Lett | 2022 | 34858525 | PubTator, text mining | PubMed |
| Multispectral optoacoustic tomography for non-invasive disease phenotyping in pediatric spinal muscular atrophy patients. | Photoacoustics | 2022 | 34849338 | PubTator, text mining | PubMed |
| Antisense oligonucleotide: A promising therapeutic option to beat COVID-19. | Wiley Interdiscip Rev RNA | 2022 | 34842345 | PubTator, text mining | PubMed |
| Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme. | Dev Med Child Neurol | 2022 | 34839535 | PubTator, text mining | PubMed |
| Drug delivery approaches for HuR-targeted therapy for lung cancer. | Adv Drug Deliv Rev | 2022 | 34822926 | PubTator, text mining | PubMed |
| Cell-penetrating peptide-conjugated Morpholino rescues SMA in a symptomatic preclinical model. | Mol Ther | 2022 | 34808387 | PubTator, text mining | PubMed |
| Premature delivery in the domestic sow in response to in utero delivery of AAV9 to fetal piglets. | Gene Ther | 2022 | 34803165 | PubTator, text mining | PubMed |
| Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics. | Mol Ther | 2022 | 34793975 | PubTator, text mining | PubMed |
| Magnetic resonance reveals mitochondrial dysfunction and muscle remodelling in spinal muscular atrophy. | Brain | 2022 | 34788410 | PubTator, text mining | PubMed |
| Exon-independent recruitment of SRSF1 is mediated by U1 snRNP stem-loop 3. | EMBO J | 2022 | 34779515 | PubTator, text mining | PubMed |
| Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management. | Pharmacoeconomics | 2022 | 34761360 | PubTator, text mining | PubMed |
| Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. | Brain | 2022 | 34677606 | PubTator, text mining | PubMed |
| Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA). | Pharmacoeconomics | 2022 | 34658008 | PubTator, text mining | PubMed |
| Rare Variants in RPPH1 Real-Time Quantitative PCR Control Assay Binding Sites Result in Incorrect Copy Number Calls. | J Mol Diagn | 2022 | 34656763 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=54